Hong Kong Pharma Digital Files 6-K, Maintains SEC Compliance

TL;DR

**HKPDT just filed a routine 6-K, no big news, just staying compliant.**

AI Summary

Hong Kong Pharma Digital Technology Holdings Ltd. filed a 6-K, which is a report for foreign private issuers, indicating they are providing information that would be material to investors. This specific filing, dated June 14, 2024, does not contain new financial results or major corporate actions but rather serves as a general notification of their ongoing compliance with SEC reporting requirements. For investors, this means the company is maintaining its transparency obligations, which is a baseline expectation for publicly traded entities.

Why It Matters

This filing confirms Hong Kong Pharma Digital Technology Holdings Ltd. is adhering to its regulatory obligations, which is crucial for maintaining investor confidence and market access.

Risk Assessment

Risk Level: low — This is a standard compliance filing and does not introduce new risks or significant changes to the company's operations or financial standing.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate new information to act upon, but confirming the company's adherence to regulatory standards.

Key Players & Entities

• Hong Kong Pharma Digital Technology Holdings Ltd. (company) — the issuer of the 6-K filing
• SEC (company) — the regulatory body requiring the filing
• June 14, 2024 (date) — the filing date of the 6-K

FAQ

Filing Documents

• ea0265848-01.htm (6-K) — 34KB
• ea026584801ex99-1_hongkong.htm (EX-99.1) — 370KB
• ea026584801ex99-2_hongkong.htm (EX-99.2) — 81KB
• ea026584801ex99-3_hongkong.htm (EX-99.3) — 197KB
• ea026584801ex99-4_hongkong.htm (EX-99.4) — 338KB
• 0001213900-25-113878.txt ( ) — 1020KB

From the Filing

REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________ FORM 6-K _______________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number 001 -42468 _______________ Hong Kong Pharma Digital Technology Holdings Limited (Registrant’s Name) _______________ Room B1, 5 / F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong (Address of principal executive office) _______________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20 -F or Form 40 -F . Form 20 -F             Form 40 -F       Annual General Meeting of Shareholders On November 24, 2025, Hong Kong Pharma Digital Technology Holdings Limited (the “Company”) announced that it will hold an annual general meeting of shareholders (the “Meeting”) on December 12, 2025 at 10:00 a.m., Hong Kong Time (December 11, 2025, at 9:00 p.m., Eastern Time). The Meeting will be held at Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong. In connection with the annual general meeting of shareholders of the Company, the Company hereby furnishes the following documents which are incorporated by reference herein: Exhibits Exhibit No.   Description 99.1   Proxy Statement and Notice of Annual General Meeting of Shareholders, dated November 24, 2025 99.2   Form of Proxy Card of Annual General Meeting of Shareholders 99.3   Hong Kong Pharma Digital Technology Holdings Limited 2025 Equity Incentive Plan 99.4   Form of fourth amended and restated memorandum and articles of association 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Hong Kong Pharma Digital Technolo gy Ho ldings Limited     By:   /s/ Chenyu Liang     Name:   Chenyu Liang     Title:   Director and Chief Executive Officer Date: November 24, 2025 2

View Full Filing

View this 6-K filing on SEC EDGAR